Tasia Amelia

Ms. Tasia Amelia

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
TATasia Amelia
Tasia Amelia
RKRahmana Emran Kartasasmita
Rahmana Emran Kartasasmita
TOTomohiko Ohwada
Tomohiko Ohwada
Daryono Hadi TjahjonoDaryono Hadi Tjahjono
Daryono Hadi Tjahjono
Lung cancer has a high prevalence, with a growing number of new cases and mortality every year. Furthermore, the survival rate of patients with non-small-cell lung carcinoma (NSCLC) is still quite low in the majority of cases. Despite the use of conventional therapy such as tyrosine kinase inhibitor for Epidermal Growth Factor Receptor (EGFR), which is highly expressed in most NSCLC cases, there was still no substantial improvement in patient survival. This is due to the drug’s ineffectiveness and high rate of resistance among individuals with mutant EGFR. Therefore, the development of new inhibitors is urgently needed. Understanding the EGFR structure, including its kinase domain and other parts of the protein, and its activation mechanism can accelerate the discovery of novel compounds targeting this protein. This study described the structure of the extracellular, transmembrane, and intracellular domains of EGFR. This was carried out along with identifying the binding pose of commercially available inhibitors in the ATP-binding and allosteric sites, thereby clarifying the research gaps that can be filled. The binding mechanism of inhibitors that have been used clinically was also explained, thereby aiding the structure-based development of new drugs.

25 March 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
TATasia Amelia
Tasia Amelia
JVJacobus P. D. van Veldhoven
Jacobus P. D. van Veldhoven
MFMatteo Falsini
Matteo Falsini
RLRongfang Liu
Rongfang Liu
LHLaura H. Heitman
Laura H. Heitman
AIAd Ijzerman
Ad Ijzerman
In this study, we determined the crystal structure of an engineered human adenosine A2A receptor bound to a partial agonist and compared it to structures cocrystallized with either a full agonist or an antagonist/inverse agonist. The interaction between the partial agonist, belonging to a class of dicyanopyridines, and amino acids in the ligand binding pocket inspired us to develop a small library of derivatives and assess their affinity in radioligand binding studies and potency and intrinsic activity in a functional, label-free, intact cell assay. It appeared that some of the derivatives retained the partial agonist profile, whereas other ligands turned into inverse agonists. We rationalized this remarkable behavior with additional computational docking studies.

8 September 2019 in Medicinal Research Reviews
Verified
Journal Article
Open access
PDF file
AMArnault Massink
Arnault Massink
TATasia Amelia
Tasia Amelia
AKAlex Karamychev
Alex Karamychev
AIAd Ijzerman
Ad Ijzerman
The function of G protein‐coupled receptors (GPCRs) can be modulated by compounds that bind to other sites than the endogenous orthosteric binding site, so‐called allosteric sites. Structure elucidation of a number of GPCRs has revealed the presence of a sodium ion bound in a conserved allosteric site. The small molecule amiloride and analogs thereof have been proposed to bind in this same sodium ion site. Hence, this review seeks to summarize and reflect on the current knowledge of allosteric effects by amiloride and its analogs on GPCRs. Amiloride is known to modulate adenosine, adrenergic, dopamine, chemokine, muscarinic, serotonin, gonadotropin‐releasing hormone, GABAB, and taste receptors. Amiloride analogs with lipophilic substituents tend to be more potent modulators than amiloride itself. Adenosine, α‐adrenergic and dopamine receptors are most strongly modulated by amiloride analogs. In addition, for a few GPCRs, more than one binding site for amiloride has been postulated. Interestingly, the nature of the allosteric effect of amiloride and derivatives varies considerably between GPCRs, with both negative and positive allosteric modulation occurring. Since the sodium ion binding site is strongly conserved among class A GPCRs it is to be expected that amiloride also binds to class A GPCRs not evaluated yet. Investigating this typical amiloride‐GPCR interaction further may yield general insight in the allosteric mechanisms of GPCR ligand binding and function, and possibly provide new opportunities for drug discovery.

14 October 2021 in ACS Omega
Verified
Journal Article
Open access
WYWiwiet Yuniati
Wiwiet Yuniati
TATasia Amelia
Tasia Amelia
SISlamet Ibrahim
Slamet Ibrahim
SDSophi Damayanti
Sophi Damayanti
Formaldehyde has been reported to be a potential human carcinogen due to its toxicity. However, formaldehyde releaser substances are still widely used as a preservative in cosmetics. Researchers have developed various methods for determining formaldehyde. One of the problems involved in the standard method is that of obtaining a derivatization agent, especially for routine analysis in the National Agency of Drug and Food, Indonesia. Therefore, this study aimed to develop a new method using gas chromatography-mass spectrometry (GC-MS) and gas chromatography-flame ionization detection (GC-FID). The significant modifications involved optimizations of five series of concentrations of p-toluenesulfonic (PTS) acid in ethanol (acidified ethanol), used as the derivatization agent, and the conditions of time and temperature of the reaction to yield the highest peak area. In addition, sample analysis was also carried out using the 2,4-dinitrophenylhydrazine (DNPH) method with high-performance liquid chromatography (HPLC) to compare the quantification results. The validated method showed intraday and interday precision, an accuracy (% RSD) of less than 3.7%, confidence interval 95.0–105.0%, a limit of detection and quantitation of 0.0099 and 0.0329 μg/mL (for DNPH by HPLC-DAD), 0.0158 and 0.0528 μg/mL (for PTS by SHS-GC-MS), and 1.1287 and 3.7625 μg/mL (for PTS liquid by GC-FID), respectively. These results have met the requirements for a validated analytical method and could be applied for routine analysis.

15 September 2023 in Heliyon
Verified
Journal Article
Open access
ASAnjar Hermadi Saputro
Anjar Hermadi Saputro
TATasia Amelia
Tasia Amelia
AMAndhika B. Mahardhika
Andhika B. Mahardhika
AWAty Widyawaruyanti
Aty Widyawaruyanti
TWTutik Sri Wahyuni
Tutik Sri Wahyuni
SDSophi Damayanti
Sophi Damayanti
Hepatitis C is still a serious liver case of health. Up to now the development of anti-Hepatitis C Virus (HCV) drugs is challenging, especially the development of natural material compounds as anti-HCV. In the present study, we evaluated the probability of α-mangostin, piperine, and β-sitosterol as anti-HCV with the in silico and in vitro approaches. Molecular docking was performed between nonstructural protein 5B (NS5B, PDB ID 3FQL) with α-mangostin, piperine, and β-sitosterol by Autodock Tools® and BIOVIA Discovery Studio®. Subsequently, molecular dynamics simulations were conducted for 200 ns, evaluating the dynamic interaction between the ligands and the viral protein NS5B. Furthermore, compound characterization at the hepatocarcinoma cell line was employed. α-Mangostin with NS5B complex demonstrated the most negative binding free energy value based on MM-PBSA calculation with a value of −9.13 kcal/mol. In vitro test showed that IC50 of α -mangostin was 2.70 ± 0.92 μM, IC50 of piperine was 52.18 ± 3.21 μM, IC50 of β-sitosterol was >100 μM. α-Mangostin can serve as a valuable lead compound for further development of the anti-HCV.

10 August 2020 in ACS Omega
Verified
Journal Article
Open access
RKRahmana E. Kartasasmita
Rahmana E. Kartasasmita
FKFransiska Kurniawan
Fransiska Kurniawan
TATasia Amelia
Tasia Amelia
CDChandrini M. Dewi
Chandrini M. Dewi
HHHarmoko Harmoko
Harmoko Harmoko
YPYoga Pratama
Yoga Pratama
Anthraquinone (AQ) levels in some Indonesian dried tea leaves samples from different plantation areas and their brewed tea samples were determined by gas chromatography–tandem mass spectrometry methods. The mean lower bound, middle bound, and upper bound of AQ levels in 59 dried tea leaves samples were 82.2, 82.8, and 83.4 μg/kg, respectively, while their 95%th percentile values were identical at 190.3 μg/kg (0.1903 mg/kg). In a transfer rate study, the mean and 95%th AQ levels in 30 dried tea leaves samples with AQ level ≥ LOQ (limit of quantification) were 128.6 and 194.5 μg/kg (0.1945 mg/kg), while those of their corresponding brewed tea samples were 2.1 and 3.4 μg/kg, respectively. The mean and 95%th transfer rates of AQ into brewed tea samples were 51.99 and 88.17%. Using these data and taking into account daily tea consumption, calculated cancer potency slope factor, benchmark dose of 10% effect at lower bound 95% confidence interval of AQ, and average body weight, the risk characterization due to exposure to this compound from tea consumption was calculated and stated as incremental lifetime cancer risk (ILCR) and margin of exposure (MOE). The overall results revealed that AQ levels in dried tea leaves up to the highest level found in the samples lead to an ILCR of not more than 10–6 and an MOE of not less than 104 and hence was predicted to give sufficient consumer protection.